Clinical trials
Phase 3 Esophageal Squamous Cell Carcinoma trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 6 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 13 |
| Unknown status | 12 |
| Active, not recruiting | 3 |
| Not yet recruiting | 2 |
| Terminated | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 6 |
| Sun Yat-sen University | 6 |
| The First Affiliated Hospital of Henan University of Science and Technology | 6 |
| BeiGene | 3 |
| Henan Cancer Hospital | 3 |
| Merck Sharp & Dohme LLC | 2 |
| Sichuan Cancer Hospital and Research Institute | 2 |
| AstraZeneca | 1 |
| Beijing Konruns Pharmaceutical Co., Ltd. | 1 |
| CStone Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Esophageal Squamous Cell Carcinoma | 46 |
| Esophageal Neoplasms | 6 |
| Carcinoma, Squamous Cell | 1 |
| Esophageal Diseases | 1 |
| Gastrointestinal Diseases | 1 |
| Neoplasm Metastasis | 1 |
| Neoplasms, Squamous Cell | 1 |
| Recurrence | 1 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.